Form 4: Lemaitre Vascular Director John A. Roush Reports Acquisition of Shares
SEC Form 4 Filing
Director John A. Roush reports acquiring shares of Lemaitre Vascular Inc. through the settlement of performance share units and dividend equivalent rights.
Summary
- On February 29, 2024, John A. Roush, a director of Lemaitre Vascular Inc. (LMAT), acquired 593 shares of common stock upon the settlement of a Performance Share Unit (PSU) award.
- These shares were acquired at a price of $0.
- Roush also acquired 1 share upon the release of dividend equivalent rights.
- Following these transactions, Roush directly owns 9,778 shares of LMAT common stock.
- The PSU award was granted on December 12, 2022, and vests in installments.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment about the company's performance or prospects.
Positives
- The acquisition of shares by a director could be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
This Form 4 filing is a routine disclosure related to insider transactions and provides transparency to the market regarding the holdings of company directors.
Stakeholder Impact
- Shareholders are informed about changes in ownership by company insiders.
Key Dates
| Date | Description |
|---|---|
| 2022-12-12 | Date of grant for the Performance Share Unit (PSU) award. |
| 2024-02-29 | Date of transaction: acquisition of shares upon settlement of PSU and release of dividend equivalent rights. |
| 2024-03-04 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.